‘Global Syringes Market Worth Over $15 Billion In 2017’ Says Visiongain Report

17 August 2017
Pharma

Visiongain’s new report Global Syringes Market Forecast 2017-2027: Revenue Prospects by Syringe Type (Reusable, Disposable), Material (Glass, Plastic), Product Type (Insulin, Tuberculin, Allergy, Other), End User (Hospitals, Homecare, Other) and Geography indicates that the Global Syringes market will see over $15bn in revenue in 2017.
The lead analyst of the report said:

“The increase in the demand for disposable syringes such as prefilled and safety syringes compared to others is extraordinarily high in North America in the upcoming years owing to the increasing prevalence rate of needle-stick injuries, increasing government funding for the use of these syringes in hospital settings, and an aging population with high incidence of chronic diseases.

Growing research on automatic safety syringes is driving the sales of safety syringes since the increasing demand for use in developed nations and more preference to automatic retractable syringes over manual syringes as they are safer and easier to handle.

Furthermore, increasing demand for point-of-care treatment is driving the market for disposable syringes market coupled with patient preference for self-administration and the increasing geriatric population. Moreover, the higher level of use of biological drugs (mostly as injectable drugs) is providing a small, yet additional push for market growth over the forecast period”

The 250-page report contains 218 tables, charts and graphs that add visual analysis in order to explain developing trends within the Global Syringes market. Visiongain provides revenue forecasts for the period 2017-2027 for the leading Global Syringes submarkets, segmented by syringe type, including forecasts for reusable/sterilisable and disposable syringes. The market is also segmented by material, with forecasts for glass and plastic syringes from 2017-2027. In addition, the market is segmented by product type, with forecasts for insulin syringes, tuberculin syringes, syringes used to deliver allergy medication and others. Finally, the global syringes market is segmented by end-user, with forecasts for hospitals, homecare and other settings.

The 250-page report offers market forecasts and analysis for 21 key national markets. In addition, the report contains a dedicated leading companies’ chapter covering 10 companies leading the Global Syringes field in detail.

The Global Syringes Market Forecast 2017-2027: Revenue Prospects by Syringe Type (Reusable, Disposable), Material (Glass, Plastic), Product Type (Insulin, Tuberculin, Allergy, Other), End User (Hospitals, Homecare, Other) and Geography report will be of value to anyone who wants to better understand the Global Syringes market and its various segments. It will be useful for businesses who wish to better comprehend the part of the market they are already involved in, or those wishing to enter or expand into a different regional or technical part of the global syringes industry.
Notes for Editors
If you are interested in a more detailed overview of this report, please send an e-mail to sara.peerun@visiongainglobal.com or call her on +44 (0) 207 336 6100

About visiongain
Visiongain is one of the fastest-growing and most innovative independent media companies in Europe. Based in London, UK, visiongain produces a host of business-to-business conferences, newsletters, management reports and e-zines focusing on the automotive, chemical, cyber, defence, energy, pharmaceutical, materials and telecoms sectors.

Visiongain publishes reports produced by its in-house analysts, who are qualified experts in their field. Visiongain has firmly established itself as the first port of call for the business professional who needs independent, high-quality, original material to rely and depend on.

Recent News

“Global Vaccines Sales market set to grow to $75bn by 2024” says new Visiongain report

Progress in R&D in the therapeutic vaccine field will yield revolutionary results and answer unmet medical needs. This will also lead to more innovative approaches to vaccine development.

25 June 2019

Read

“Global Inflammatory Bowel Diseases (IBD) Drug Market is estimated to reach $8.6bn by 2024” says new Visiongain report

Revenue growth will be driven by rising incidence and prevalence owing to modern lifestyles and improved awareness and diagnosis.

21 June 2019

Read

“Top 25 Vaccines market set to grow to $41bn by 2024” says new Visiongain report

There is an increasing focus to identify diseases that currently do not have a vaccine.

20 June 2019

Read

“Global Ophthalmic Drugs market set to grow to $33bn by 2024” says new Visiongain report

The market for ophthalmic drugs is a growing one.

17 June 2019

Read

Kelloggs
3m
Thales
Shell
TEVA
Lockheed-Martin
Pfizer
Raytheon
Halliburton
Du-Pont
Honeywell
Daimler
BASF
Bayer
BP
BAE-Systems
Unilever